BTT-3033

Description: BTT-3033 is an orally active and potent alpha2beta1 (EC50: 130 nM) inhibitor with an affinity for the alpha2I domain, inhibiting platelet binding to collagen I and cell proliferation. BTT-3033 induces apoptosis and can be used to study prostate cancer, inflammation, and cardiovascular disease. Target: Apoptosis, Integrin. Smiles: CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1. References: Liisa Nissinen, et al. Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 Jun,3(3):e00146.